TapImmune Appoints Michael J. Loiacono As Chief Financial Officer >GX1C.BE
DOW JONES & COMPANY, INC. 8:30 AM ET 8/25/2016
Symbol Last Price Change
TPIV 0.475up 0 (0%)
QUOTES AS OF 03:50:48 PM ET 08/24/2016
TapImmune Appoints Michael J. Loiacono as Chief Financial Officer
Accomplished Financial Director & CFO of Public Companies
PR Newswire
JACKSONVILLE, Florida, August 25, 2016
JACKSONVILLE, Florida, August 25, 2016 /PRNewswire/ --
TapImmune Inc. (TPIV) , a clinical-stage immuno-oncology company specializing in the development of innovative peptide and gene-based immunotherapeutics and vaccines for the treatment of cancer & metastatic disease, is pleased to announce the appointment of Michael J. Loiacono as its Chief Financial Officer and Chief Accounting Officer. Michael will also act as Corporate Secretary. Michael has served an advisory role to the Company as finance consultant to TapImmune(TPIV) since March 2016.
Michael served as CFO of Global Axcess Corporation, a publicly-traded company, from 2006-2013 where he was responsible for the overall strategy of the company including capital raises, mergers & acquisitions, corporate finance, treasury, accounting and investor relations. Upon the acquisition of Global Axcess by FCTI, Inc., he was responsible for the company's strategic development including new products and services, entrance into new markets and maximizing gross and net revenues. In 2009, he was named the "Jacksonville Florida Ultimate CFO of the year" by the Jacksonville Business Journal.
Prior to Global Axcess/FCTI Michael held various positions of increasing responsibility in finance management through several private and publicly-traded organizations. He has a degree in Business Management from Rutgers University, Business School, NJ.
Dr. Glynn Wilson, Chairman & CEO of TapImmune(TPIV), stated, "We welcome Michael to a key position in the TapImmune(TPIV) management team. As an advisor to the Company, Michael has clearly demonstrated his financial skills and ability to professionally lead our finance and accounting functions consistent with our projected up-list to the Nasdaq National Markets."
"It's truly an exciting opportunity to join an industry-leader like TapImmune(TPIV) and be a part of the management team," said Mr. Loiacono, "The Company has become a leader in the area of immuno-oncology as a result of innovative science, passionate employees and talented researchers. I look forward to working with this fantastic team as we continue to forge ahead in this very important industry and bring increased value to our shareholders."
News 
Market Data 
Discover 
